BBIO
BridgeBio Pharma, Inc.
$66.80
-1.11%
$13.1B
No data for this timeframe.
Vol
Market Cap$13.1B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$8.6B
Inst. Activity28 buys / 13 sells
Insider Activity0B / 17S
Insider Net $-$11.0M
SEC Reports9
Press Releases6
Congressional4 trades
Recent Activity
Nov 27, 2026
fda_pdufa
PDUFA: BBIO — BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) — 2026-11-27
FDA target action date 2026-11-27 for BBIO (BridgeBio Pharma, Inc.). Drug: BBP-418. Indication: limb
Jun 5, 2026
Insider
Kumar Neil sold 7,147 shares
Chief Executive Officer @ $67.20 ($480.3K)
Jun 4, 2026
Insider
Kumar Neil sold 2,200 shares
Chief Executive Officer @ $65.72 ($144.6K)
May 27, 2026
Press
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe
Impact 8/10
May 26, 2026
SEC
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day
CLUSTER — Impact 5/10
May 21, 2026
SEC
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stoc
144 — Impact 3/10
May 21, 2026
Insider
Kumar Neil sold 2,256 shares
Chief Executive Officer @ $67.57 ($152.4K)
May 19, 2026
SEC
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and
CLUSTER — Impact 3/10
Price Targets
$102.71
+53.8% upside
Strong Buy
Current $66.80
Low $76.00
Median $100.00
High $157.00
23 analysts
$76.00
$157.00
Analyst Ratings
8Strong Buy
19Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Canaccord Genuity | INITIATE | Buy |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 26, 2026 | Raymond James | DOWNGRADE | Outperform → Market Perform |
| May 19, 2026 | Citigroup | INITIATE | Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.59 ▲ +3.5% | $-0.71 — $-0.42 | 38% YoY | 7 |
| Next Q | $-0.48 ▲ +3.0% | $-0.59 — $-0.37 | 34% YoY | 7 |
| Current FY | $-2.22 ▼ -8.4% | $-2.62 — $-1.49 | 41% YoY | 9 |
| Next FY | $0.50 ▲ +82.0% | $-1.30 — $2.12 | 122% YoY | 8 |
Latest Reports
BULLISH
Press
8/10
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe
May 27, 2026
BEARISH
CLUSTER
5/10
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day
May 26, 2026
NEUTRAL
144
3/10
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stoc
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $1.1B | — |
| JANUS HENDERSON GROUP PLC | $978.6M | ADD |
| FARALLON CAPITAL MANAGEMENT LLC | $695.5M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $600.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Kumar Neil | SELL | $480.3K |
| Jun 4, 2026 | Kumar Neil | SELL | $144.6K |
| May 21, 2026 | Kumar Neil | SELL | $152.4K |
| May 18, 2026 | Trimarchi Thomas | SELL | $677.7K |
| May 16, 2026 | Apuli Maricel | F | $311.7K |
Congressional Trades
1 members: 4 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
50 institutional holders with $8.6B total value (115,737,917 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, JANUS. Net buying activity: 28 institutions added/increased vs 13 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 14,207,757 | $1.1B | 12.3% | — |
| 3 | JANUS HENDERSON GROUP PLC | 13,179,013 | $978.6M | 11.4% | ADD +25.8% |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 9,365,463 | $695.5M | 8.1% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,080,573 | $600.1M | 7.0% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 7,759,495 | $576.2M | 6.7% | — |
| 7 | STATE STREET CORP | 4,934,320 | $366.4M | 4.3% | — |
| 8 | Invesco Ltd. | 4,592,814 | $341.1M | 4.0% | — |
| 9 | CITADEL ADVISORS LLC | 3,173,940 | $235.7M | 2.7% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 3,120,631 | $231.7M | 2.7% | — |
| 11 | D. E. Shaw & Co., Inc. | 2,545,486 | $189.0M | 2.2% | — |
| 12 | Polar Capital Holdings Plc | 2,519,306 | $187.1M | 2.2% | ADD +93.9% |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 2,483,953 | $184.5M | 2.1% | DOUBLED +130.4% |
| 14 | FRANKLIN RESOURCES INC | 2,438,925 | $181.1M | 2.1% | ADD +49.9% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,384,600 | $177.1M | 2.1% | — |
| 16 | FMR LLC | 2,343,754 | $174.0M | 2.0% | ADD +40.5% |
| 17 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1,977,080 | $146.8M | 1.7% | — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,976,094 | $146.7M | 1.7% | — |
| 19 | ALLIANCEBERNSTEIN L.P. | 1,908,907 | $146.0M | 1.7% | — |
| 20 | GOLDMAN SACHS GROUP INC | 1,897,716 | $140.9M | 1.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | ADD | 1,299,346 | 2,519,306 | +93.9% | $187.1M | 2026-Q1 |
| MORGAN STANLEY | ADD | 1,399,809 | 1,877,359 | +34.1% | $139.4M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 841,536 | 1,248,521 | +48.4% | $92.7M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 1,680,972 | 1,146,671 | -31.8% | $85.2M | 2026-Q1 |
| Clearbridge Investments, LLC | ADD | 498,329 | 951,200 | +90.9% | $70.6M | 2026-Q1 |
| Capital Research Global Investors | TRIM | 1,934,698 | 763,702 | -60.5% | $56.7M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 382,569 | 561,945 | +46.9% | $41.7M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 638,883 | 426,583 | -33.2% | $31.7M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 365,772 | — | $27.2M | 2026-Q1 |
| 1832 Asset Management L.P. | DOUBLED | 45,600 | 356,400 | +681.6% | $26.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 234,389 | 350,096 | +49.4% | $26.0M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 74,686 | 334,382 | +347.7% | $24.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 224,866 | 288,075 | +28.1% | $21.4M | 2026-Q1 |
| Erste Asset Management GmbH | ADD | 110,225 | 189,725 | +72.1% | $13.2M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | ADD | 90,755 | 139,510 | +53.7% | $10.4M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | TRIM | 204,096 | 127,219 | -37.7% | $9.4M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 62,357 | 114,884 | +84.2% | $8.0M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 54,495 | 106,911 | +96.2% | $7.9M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | DOUBLED | 30,895 | 99,916 | +223.4% | $7.4M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | 1,958 | 88,130 | +4401.0% | $6.5M | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 173,523 | 81,570 | -53.0% | $6.1M | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 38,429 | 53,621 | +39.5% | $4.0M | 2026-Q1 |
| HighTower Advisors, LLC | TRIM | 91,986 | 47,624 | -48.2% | $3.5M | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 33,513 | 44,092 | +31.6% | $3.3M | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 13,665 | 32,708 | +139.4% | $2.4M | 2026-Q1 |
6 unique insiders with 29 transactions. Net insider value: -$11.0M ($0.00 bought, $11.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,147 | $67.20 | $480.3K |
| Jun 4, 2026 | Kumar Neil | Chief Executive Officer | SELL | 2,200 | $65.72 | $144.6K |
| May 21, 2026 | Kumar Neil | Chief Executive Officer | SELL | 2,256 | $67.57 | $152.4K |
| May 18, 2026 | Trimarchi Thomas | President and CFO | SELL | 10,456 | $64.82 | $677.7K |
| May 16, 2026 | Apuli Maricel | Chief Accounting Officer | TAX W/H | 4,714 | $66.13 | $311.7K |
| May 16, 2026 | Kumar Neil | Chief Executive Officer | EXERCISE | 33,544 | — | — |
| May 16, 2026 | Kumar Neil | Chief Executive Officer | TAX W/H | 36,236 | $66.13 | $2.4M |
| May 16, 2026 | Trimarchi Thomas | President and CFO | TAX W/H | 22,781 | $66.13 | $1.5M |
| May 15, 2026 | Scott Randal W. | Director | SELL | 6,200 | $66.69 | $413.5K |
| May 15, 2026 | Scott Randal W. | Director | EXERCISE | 10,000 | $16.75 | $167.5K |
| May 8, 2026 | Kumar Neil | Chief Executive Officer | SELL | 13,973 | $66.65 | $931.3K |
| May 7, 2026 | Kumar Neil | Chief Executive Officer | SELL | 11,217 | $67.50 | $757.1K |
| Apr 30, 2026 | Apuli Maricel | Chief Accounting Officer | SELL | 2,000 | $71.58 | $143.2K |
| Apr 10, 2026 | Kumar Neil | Chief Executive Officer | SELL | 20,000 | $74.60 | $1.5M |
| Apr 9, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,200 | $73.64 | $530.2K |
| Mar 18, 2026 | Trimarchi Thomas | President and CFO | AWARD | 59,041 | — | — |
| Mar 18, 2026 | Apuli Maricel | Chief Accounting Officer | AWARD | 14,170 | — | — |
| Mar 17, 2026 | Kumar Neil | Chief Executive Officer | AWARD | 40,570 | — | — |
| Mar 17, 2026 | Kumar Neil | Chief Executive Officer | AWARD | 104,313 | — | — |
| Mar 13, 2026 | Kumar Neil | Chief Executive Officer | SELL | 9,690 | $68.36 | $662.4K |
| Mar 12, 2026 | Kumar Neil | Chief Executive Officer | SELL | 14,337 | $68.48 | $981.8K |
| Mar 10, 2026 | Valantine Hannah | Director | SELL | 8,671 | $72.00 | $624.3K |
| Mar 10, 2026 | Valantine Hannah | Director | EXERCISE | 8,671 | $27.36 | $237.2K |
| Mar 4, 2026 | Ellis Andrea | Director | EXERCISE | 64,921 | $8.45 | $548.6K |
| Feb 27, 2026 | Valantine Hannah | Director | EXERCISE | 25,484 | $48.45 | $1.2M |
| Feb 26, 2026 | Apuli Maricel | Chief Accounting Officer | SELL | 2,000 | $66.00 | $132.0K |
| Feb 19, 2026 | Kumar Neil | Chief Executive Officer | SELL | 18,923 | $71.03 | $1.3M |
| Feb 11, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,806 | $70.69 | $551.8K |
| Feb 10, 2026 | Kumar Neil | Chief Executive Officer | SELL | 14,201 | $71.80 | $1.0M |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 3 mixed, 4 neutral. Avg impact: 4.9/10.
BEARISH
CLUSTER
5/10
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market
May 26, 2026
NEUTRAL
144
3/10
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 s
May 21, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 e
May 19, 2026
MIXED
S-3ASR
6/10
BridgeBio Pharma filed an automatic shelf registration (S-3ASR) to register an unlimited amount of s
May 8, 2026
MIXED
PRESS-RELEASE
6/10
BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby
May 7, 2026
NEUTRAL
DEFA14A
4/10
Analysis based on filing metadata only — document content was unavailable
Apr 24, 2026
NEUTRAL
CLUSTER
3/10
BridgeBio Pharma CEO Kumar Neil was granted a total of 144,883 shares in non-cash awards and sold 9,
Mar 19, 2026
BEARISH
CLUSTER
7/10
BridgeBio Pharma CEO Kumar Neil sold shares worth over $1.6 million in open-market transactions, whi
Mar 16, 2026
MIXED
8-K
7/10
BridgeBio Pharma reported strong 2025 financial results driven by $502.1 million in net revenue, pri
Feb 24, 2026
BULLISH
8/10
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a P
May 27, 2026
BULLISH
8/10
BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 C
May 12, 2026
BULLISH
8/10
BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovasc
May 11, 2026
BULLISH
7/10
BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) fo
May 6, 2026
NEUTRAL
3/10
BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026
May 5, 2026
BULLISH
8/10
BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral thera
Mar 11, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 29 analysts: 8 strong buy, 19 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$102.71 mean target
+53.8% upside
Strong Buy (1.42)
$76.00 Low
$157.00 High
| Metric | Value |
|---|---|
| Current Price | $66.80 |
| Target Low | $76.00 |
| Target Mean | $102.71 |
| Target Median | $100.00 |
| Target High | $157.00 |
| # Analysts | 23 |
| Recommendation | Strong Buy (1.42) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.59 | $-0.71 | $-0.42 | 38.4% | +3.5% | 0↑ 3↓ | $0.2B | 103.8% | 7 |
| Next Q 2026-09-30 |
$-0.48 | $-0.59 | $-0.37 | 33.7% | +3.0% | 2↑ 1↓ | $0.3B | 110.3% | 7 |
| Current FY 2026-12-31 |
$-2.22 | $-2.62 | $-1.49 | 41.4% | -8.4% | 3↑ 1↓ | $1.0B | 92.2% | 9 |
| Next FY 2027-12-31 |
$0.50 | $-1.30 | $2.12 | 122.3% | +82.0% | 2↑ 1↓ | $1.6B | 68.3% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.586 | |
| 7d ago | $-0.598 | +0.013 |
| 30d ago | $-0.607 | +0.021 |
| 60d ago | $-0.522 | -0.063 |
| 90d ago | $-0.390 | -0.196 |
15 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 26, 2026 | Raymond James | DOWNGRADE | Outperform | Market Perform |
| May 19, 2026 | Citigroup | INITIATE | — | Neutral |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 8, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 29, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 28, 2026 | Mizuho | REITERATE | Outperform | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2026 | RBC Capital | INITIATE | — | Outperform |
| Mar 18, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 10, 2026 | William Blair | INITIATE | — | Outperform |
| Feb 25, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Morgan Stanley | INITIATE | — | Overweight |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 19 | 2 | 0 | 0 | 93% | |
| May 1, 2026 | 9 | 20 | 1 | 0 | 0 | 97% | |
| Apr 1, 2026 | 9 | 19 | 1 | 0 | 0 | 97% | |
| Mar 1, 2026 | 8 | 19 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 8 | 19 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 8 | 17 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 4 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | May 11, 2026 (13d) |
| Mar 19, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (21d) |
| Mar 18, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (22d) |
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (37d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Nov 27, 2026
fda_pdufa
PDUFA: BBIO — BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) — 2026-11-27
FDA target action date 2026-11-27 for BBIO (BridgeBio Pharma, Inc.). Drug: BBP-418. Indication: limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Jun 11, 2026
short_volume
Short Volume: BBIO — 76.0% short (1.0M / 1.3M)
Short: 988,519 | Exempt: 523 | TRF Vol: 1,300,194 | Short Ratio: 76.0% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: BBIO — 68.6% short (0.8M / 1.2M)
Short: 793,620 | Exempt: 31 | TRF Vol: 1,156,373 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: BBIO — 74.2% short (1.9M / 2.6M)
Short: 1,900,639 | Exempt: 151 | TRF Vol: 2,561,094 | Short Ratio: 74.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: BBIO — 90.0% short (5.3M / 5.9M)
Short: 5,286,891 | Exempt: 0 | TRF Vol: 5,875,118 | Short Ratio: 90.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
fda
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
<p><em>- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority R
May 18, 2026
short_volume
Short Volume: BBIO — 57.2% short (1.0M / 1.8M)
Short: 1,012,651 | Exempt: 213,236 | TRF Vol: 1,770,065 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
fda
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
<p><em>- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of enca
May 11, 2026
fda
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
<p><em>-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated w
May 8, 2026
other
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p>PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical com
May 8, 2026
short_volume
Short Volume: BBIO — 60.9% short (1.5M / 2.4M)
Short: 1,461,454 | Exempt: 1,694 | TRF Vol: 2,397,841 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
<p>PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, mul
May 7, 2026
earnings_calendar
BBIO Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
other
BridgeBio to Participate in May and June Investor Conferences
<p align="left">PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharm
May 6, 2026
fda
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
<p><em>- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the mo